Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CLBR vs BGLC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BGLC Wins Head-to-Head Institutional Verdict (3–0 across 6 Pillars · 5–3 Matrix Metrics)

BGLC Overall Winner 6-Pillar Tally: CLBR 0 – 3 BGLC (3 Tie) Matrix Metrics: CLBR 3 – 5 BGLC

As of Nov 20, 2026, BioNexus Gene Lab Corp (BGLC) is the stronger overall head-to-head candidate over CLBR (CLBR) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CLBR carries a Unified Composite Score of 47.5/100 (HOLD) at $10.02 (N/M Forward P/E, N/A operating margin), whereas BGLC carries 44.2/100 (HOLD) at $0.68 (N/M Forward P/E, -88.2% operating margin).

  • Composite vs. Pillar Nuance: While CLBR currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. BGLC 44.2/100 HOLD), BGLC captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–0 across the 6 pillars) due to superior fundamental profitability (-88.2% vs. N/A operating margin) and revenue trajectory (-96.6% vs. N/A YoY).
  • Technical & Structure Timing Caution: CLBR is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 35.4); meanwhile BGLC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CLBR vs BGLC
CLBR US Equity
CLBR
Institutional Equity
$10.02
-0.1% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.08β · 4% Vol
Unified Composite Score
47.5 / 100 HOLD
Tech 50.0 Fund 54.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.7%) with fading momentum, RSI 35
RSI-14: 35.4 · SMA20: $10.07 · SMA50: $10.13
BGLC NASDAQ Head-to-Head Winner
BioNexus Gene Lab Corp Common stock
Services-Medical Laboratories
$0.68
+0.0% 1D
Market Cap $2.0M
TTM Revenue $3.1M
Forward P/E N/M
Beta / 30D Vol 1.34β · 86% Vol
Unified Composite Score
44.2 / 100 HOLD
Tech 45.0 Fund 42.0 Flow 50.0 Mom 63.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.0%), weak momentum, RSI 27
RSI-14: 26.8 · SMA20: $0.89 · SMA50: $1.15

6-Pillar Scorecard Institutional Category Breakdown (CLBR 0 – 3 BGLC)

Columns: Metric · CLBR · BGLC
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale BGLC
Revenue Growth (YoY) N/A -96.6%
Earnings Growth (YoY) N/A -95.0%
TTM Revenue (USD) N/A $3.1M
Market Cap N/A $2.0M
3. Profitability & Quality BGLC
Gross Margin N/A 12.3%
Operating Margin N/A -88.2%
Net Profit Margin N/A -82.4%
Return on Equity (ROE) N/A -33.7%
4. Balance Sheet & Cash Flow BGLC
Cash Generation (TTM) N/A -$1.2M
Cash Flow Margin N/A -38.1%
Net Cash / Leverage N/A ROE $3.7M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Specialty Chemicals Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CLBR (3) vs BGLC (5)
Institutional Metric CLBR BGLC Criterion Row Edge
Market Capitalization
Scale
N/A $2.0M Larger Scale BGLC
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A -96.6% Higher Growth BGLC
Operating Margin (TTM)
Profitability
N/A -88.2% Higher Margin BGLC
Net Profit Margin
Profitability
N/A -82.4% Higher Margin BGLC
Return on Equity (ROE)
Capital Efficiency
N/A -33.7% Higher ROE BGLC
52-Week Range Position
Momentum
5% ($10–$10) 1% ($1–$5) Stronger Trend CLBR
Beta / 30D Volatility
Risk Regime
0.08β · 4% Vol 1.34β · 86% Vol Lower Realized Risk CLBR
Unified Institutional Score
Composite Signal
47.5 / 100 (HOLD) 44.2 / 100 (HOLD) Higher Composite CLBR
Trailing 12M Revenue (USD)
Operating Scale
N/A $3.1M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 12.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$1.2M ($3.7M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CLBR +42.46 pp
CLBR: -0.4% · BGLC: -42.86%
3M Horizon CLBR +54.54 pp
CLBR: -2.15% · BGLC: -56.69%
6M Horizon CLBR +67.12 pp
CLBR: -0.5% · BGLC: -67.62%
1Y Horizon CLBR +70.54 pp
CLBR: -0.5% · BGLC: -71.04%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLBR vs BGLC. Trailing 12-month operating profitability (CLBR N/A vs BGLC -88.2%) and valuation multiples (CLBR N/M vs BGLC N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CLBR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
BGLC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.1M
Gross Margin12.3%
Op. Margin-88.2%
ROE / Fwd P/E-33.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CLBR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CLBR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BGLC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BGLC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CLBR Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BGLC Moat Profile Cyclical / Execution-Driven Positioning
Specialty Chemicals Operator
Competes within the Specialty Chemicals value chain with $2.0M market capitalization and -88.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CLBR vs BGLC Key Questions & Quantitative Answers

As of Nov 20, 2026, BioNexus Gene Lab Corp (BGLC) is the stronger overall head-to-head candidate over CLBR (CLBR) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CLBR carries a Unified Composite Score of 47.5/100 (HOLD) at $10.02 (N/M Forward P/E, N/A operating margin), whereas BGLC carries 44.2/100 (HOLD) at $0.68 (N/M Forward P/E, -88.2% operating margin). Composite vs. Pillar Nuance: While CLBR currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. BGLC 44.2/100 HOLD), BGLC captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–0 across the 6 pillars) due to superior fundamental profitability (-88.2% vs. N/A operating margin) and revenue trajectory (-96.6% vs. N/A YoY). Technical & Structure Timing Caution: CLBR is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 35.4); meanwhile BGLC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BGLC leads the Growth & Scale pillar: CLBR posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with BGLC at -96.6% YoY revenue growth and -95.0% YoY earnings growth on $3.1M TTM revenue (12.3% gross margin, -88.2% operating margin). On trailing 12-month operating scale, CLBR generates N/A in USD-normalized revenue versus $3.1M for BGLC. In operating R&D and SG&A reinvestment, CLBR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BGLC.

CLBR and BGLC trade at balanced relative valuation multiples. CLBR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas BGLC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (-38.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CLBR (N/A ROE) versus BGLC (-33.7% ROE) capital efficiency.

In options market volatility and institutional positioning, CLBR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.08β · 4% Vol realized risk). By comparison, BGLC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 86% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.